The management of factor XI deficiency

Area of Science:

• Hematology
• Coagulation Disorders

Background:

• Factor XI deficiency presents a more variable bleeding tendency compared to hemophilia A or B.
• Both severely and partially deficient individuals may experience excessive bleeding, particularly after surgery.
• Careful preoperative planning is essential for managing patients with Factor XI deficiency.

Purpose of the Study:

• To review the clinical presentation of Factor XI deficiency.
• To discuss available therapeutic options for managing bleeding in Factor XI deficiency.
• To evaluate the risks and benefits of various treatment modalities.

Main Methods:

• Review of existing literature on Factor XI deficiency and its management.
• Analysis of therapeutic options including fresh frozen plasma, factor XI concentrates, fibrin glue, antifibrinolytic drugs, and desmopressin.
• Consideration of the advantages and risks associated with each treatment modality.

Main Results:

• Factor XI concentrate may be beneficial for high-risk procedures in young, severely deficient patients.
• Thrombotic events have been associated with factor XI concentrate use in older patients.
• Use of virally inactivated fresh frozen plasma is preferred.
• Fibrin glue shows promise but requires further investigation.

Conclusions:

• Management of Factor XI deficiency requires individualized surgical planning and careful consideration of treatment risks.
• Factor XI concentrates and fresh frozen plasma are key therapeutic options, with specific indications and contraindications.
• Fibrin glue represents a potential adjunctive therapy warranting further research.